Organization | Kaleido Biosciences

Kaleido Biosciences Report issue

For profit Phase 2

Founded: Bedford MA United States (2015)

Status: Defunct (2022)

Organization Overview

First Clinical Trial

2015

NCT02628652

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Kaleido Biosciences | Kaleido Boisciences

Active Ingredients

Drugs in Phase 2 Trials (1)

kb195 (3 trials)

Drugs in Other Trials (8)

gluco-galacto-oligosaccharide (1 trial)

kb109 (3 trials)

kb174 (2 trials)

kb295 (1 trial)

lactulose (cephulac) (1 trial)

maltodextrin (2 trials)

oligofructose (1 trial)

polydextrose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Disease (Phase 2)

Urea Cycle Disorders, Inborn (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 11
# of Trial APIs: 9